ARS Pharmaceuticals Inc. Common Stock (SPRY)

About SPRY

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

195

Website

ars-pharma.com

Fundamentals

1-day range

$5$5.84

Market cap

$542.20M

P/E (trailing)

—

P/E (forward)

-6.35

EPS (trailing)

$-2.18

Dividend yield

—

Beta

0.97

Avg. volume

2.05M

Forecasts

4 analyst ratings

ARS Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SPRY

  ARS Pharmaceuticals Inc. Common Stock

  $5.89

  ▼ 2.32%
  Market cap $542.20MP/E —
  $4.91$15.09
• CBIO

  Crescent Biopharma Inc. Common Stock

  $17.74

  ▼ 0.14%
  Market cap $552.33MP/E —
  $8.72$27.41
• ARVN

  Arvinas Inc. Common Stock

  $9.16

  ▼ 0.87%
  Market cap $520.04MP/E 62.96
  $6.97$14.51
• MPLT

  MapLight Therapeutics Inc. Common Stock

  $12.64

  ▲ 0.80%
  Market cap $569.09MP/E —
  $9.1$40.43
• CRMD

  CorMedix Inc. Common Stock

  $8.31

  ▼ 0.06%
  Market cap $592.31MP/E 3.53
  $6.13$14.96
• QTTB

  Q32 Bio Inc. Common Stock

  $15.01

  ▼ 7.06%
  Market cap $451.37MP/E 15.71
  $1.62$23.57
• SGMT

  Sagimet Biosciences Inc. Series A Common Stock

  $10.55

  ▼ 1.86%
  Market cap $441.53MP/E —
  $4.5$11.15

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
  Benzinga · 8/14/2026
• Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
  Benzinga · 8/14/2026
• ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/14/2026
• ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
  Benzinga · 8/13/2026
• 12 Health Care Stocks Moving In Thursday's After-Market Session
  Benzinga · 8/13/2026
• ARS Pharmaceuticals Q2 EPS $(0.63) Misses $(0.48) Estimate, Sales $33.658M Beat $31.321M Estimate
  Benzinga · 8/13/2026

• Casale Donn · July 1, 2026 · Grant

  898.5K
• Kelly Michael · June 24, 2026 · Grant

  30.0K
• Dadoo Rajeev · June 24, 2026 · Grant

  30.0K
• Shah Pratik · June 24, 2026 · Grant

  30.0K
• Islam Saqib · June 24, 2026 · Grant

  30.0K
• Shawver Laura · June 24, 2026 · Grant

  30.0K
• Peter A. Thompson · June 24, 2026 · Grant

  30.0K
• RA Capital Healthcare Fund LP · June 24, 2026 · Grant

  30.0K
• Brent L. Saunders · June 24, 2026 · Grant

  30.0K
• SCHNEIDER PHILLIP M · June 24, 2026 · Grant

  30.0K
• Karas Eric · June 12, 2026 · Option Exercise

  25.0K @ $1.5
• Karas Eric · June 12, 2026 · Sale

  25.0K @ $10
• Fitzpatrick Alexander A · June 12, 2026 · Sale

  3.4K @ $10

Institutional Ownership

March 31, 2026

Total shares held

92.10M

Total value held

$723.19M

Institutional holders

196